Relationships between performance on the cogstate brief battery, neurodegeneration, and aβ accumulation in cognitively normal older adults and adults with MCI

Archives of Clinical Neuropsychology

Volumn 30, Issue 1, 2015, Pages 49-58

  Lim, Yen Ying ^a,b   Pietrzak, Robert H ^c   Bourgeat, Pierrick ^d   Ames, David ^a,e   Ellis, Kathryn A ^a,e   Rembach, Alan ^a   Harrington, Karra ^a   Salvado, Olivier ^d   Martins, Ralph N ^f   Snyder, Peter J ^b   Masters, Colin L ^a   Rowe, Christopher C ^a,g   Villemagne, Victor L ^a,g   Maruff, Paul ^a,h  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b BROWN UNIVERSITY   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d CSIRO   (Australia)

^e NATIONAL AGEING RESEARCH INSTITUTE   (Australia)

^f EDITH COWAN UNIVERSITY   (Australia)

^g AUSTIN HEALTH   (Australia)

^h Scientific Division   (Australia)

Author keywords

Episodic memory; Hippocampal volume; MCI; Neuropsychological assessment; Preclinical AD; amyloid

Indexed keywords

2-(4'-(METHYLAMINO)PHENYL)-6-HYDROXYBENZOTHIAZOLE; AMYLOID BETA PROTEIN; ANILINE DERIVATIVE; APOLIPOPROTEIN E; CARBON; THIAZOLE DERIVATIVE;

AGED; AGING; ATROPHY; COMPLICATION; DIAGNOSTIC USE; FEMALE; GENETICS; HIPPOCAMPUS; HUMAN; MALE; MEMORY DISORDERS; METABOLISM; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; NERVE DEGENERATION; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; SCINTISCANNING; SHORT TERM MEMORY; STATISTICAL MODEL; TIME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AGING; AMYLOID BETA-PEPTIDES; ANILINE COMPOUNDS; APOLIPOPROTEINS E; ATROPHY; CARBON ISOTOPES; FEMALE; HIPPOCAMPUS; HUMANS; LINEAR MODELS; MAGNETIC RESONANCE IMAGING; MALE; MEMORY DISORDERS; MEMORY, SHORT-TERM; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; NERVE DEGENERATION; NEUROPSYCHOLOGICAL TESTS; POSITRON-EMISSION TOMOGRAPHY; THIAZOLES; TIME FACTORS;

EID: 84925305188     PISSN: 08876177     EISSN: 18735843     Source Type: Journal    
DOI: 10.1093/arclin/acu068     Document Type: Article

References (31)

1. Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., et al. (2012). Clinical and biomarker changes in Dominantly Inherited Alzheimer's disease. The New England Journal of Medicine, 367 (9), 795-804.
2. Bennett, D. A., Schneider, J. A., Wilson, R. S., Bienias, J. L., & Arnold, S. E. (2004). Neurofibrillary tangles mediate the association of amyloid load with clinical Alzheimer disease and level of cognitive function. Archives of Neurology, 61 (3), 378-384.
3. Chételat, G., Villemagne, V. L., Villain, N., Jones, G., Ellis, K. A., Ames, D., et al. (2012). Accelerated cortical atrophy in cognitively normal elderly with high b-amyloid deposition. Neurology, 78, 477-484.
4. Cohen, J. (1992). A power primer. Psychological Bulletin, 112, 155-159.
5. Collins, D. L., Zijdenbos, A. P., Kollokian, V., Sled, J. G., Kabani, N. J., Holmes, C. J., et al. (1998). Design and construction of a realistic digital brain phantom. IEEE Transactions on Medical Imaging, 17 (3), 463-468.
6. Doraiswamy, P. M., Sperling, R. A., Coleman, R. E., Johnson, K. A., Reiman, E. M., Davis, M. D., et al. (2012). Amyloid-b assessed by florbetapir F 18 PET and 18-month cognitive decline. Neurology, 79, 1636-1644.
7. Doraiswamy, P. M., Sperling, R. A., Johnson, K., Reiman, E. M., Wong, T. Z., Sabbagh, M. N., et al. (2014). Florbetapir F 18 amyloidPETand 36-month cognitive decline: A prospective multicenter study. Molecular Psychiatry, 19 (9), 1044-1051.
8. Dore, V., Villemagne, V. L., Bourgeat, P., Fripp, J., Acosta, O., Chetelat, G., et al. (2013). Cross-sectional and longitudinal analysis of the relationship betweenAb deposition, cortical thickness, and memory in cognitively unimpaired individuals and in Alzheimer's disease. JAMA Neurology, 70 (7), 903-911.
9. Ellis, K. A., Bush, A. I., Darby, D., De Fazio, D., Foster, J., Hudson, P., et al. (2009). The Australian imaging, biomarkers and lifestyle (AIBL) study of aging: Methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease. International Psychogeriatrics, 21, 672-687.
10. Hu, L., & Bentler, P. M. (1999). Cutoff criteria for fit indexes in covariance structure analysis: Conventional criteria versus new alternatives. Structural Equation Modeling, 6, 1-55.
11. Hu, L., & Bentler, P.M.(1998). Fit indices in covariance structure modeling: Sensitivity to under-parameterized model misspecification. Psychological Methods, 3, 424-453.
12. Jack, C. R., & Holtzman, D. M. (2013). Biomarker modeling of Alzheimer's disease. Neuron, 80 (6), 1347-1358.
13. Jack, C. R., Wiste, H. J., Knopman, D. S., Vemuri, P., Mielke, M. M., Weigand, S. D., et al. (2014). Rates of B-amyloid accumulation are independent of hippocampal neurodegeneration. Neurology, 82, 1605-1612.
14. Jack, C. R., Wiste, H. J., Lesnick, T. G., Weigand, S. D., Knopman, D. S., Vemuri, P., et al. (2013). Brain b-amyloid load approaches a plateau. Neurology, 80, 1-7.
15. Johnson, K. A., Sperling, R. A., Gidicsin, C. M., Carmasin, J. S., Maye, J. E., Coleman, R. E., et al. (2013). Florbetapir (F18-AV-45)PETto assess amyloid burden in Alzheimer's disease dementia, mild cognitive impairment, and normal aging. Alzheimer's & Dementia, 12, S1552-S5260.
16. Lim, Y. Y., Ellis, K. A., Harrington, K., Ames, D., Martins, R. N., Masters, C. L., et al. (2012). Use of the cogstate brief battery in the assessment of Alzheimer's disease related cognitive impairment in the Australian imaging, biomarker and lifestyle (AIBL) study. Journal of Clinical and Experimental Neuropsychology, 34 (4), 345-358.
17. Lim, Y.Y., Ellis, K. A., Pietrzak, R. H., Ames, D., Darby, D., Harrington, K., et al. (2012). Stronger effect of amyloid load thanAPOEgenotype on cognitive decline in healthy older adults. Neurology, 79, 1645-1652.
18. Lim, Y.Y., Maruff, P., Pietrzak, R. H., Ames, D., Ellis, K. A., Harrington, K., et al. (2014). Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer's disease. Brain, 137, 221-231.
19. Lim, Y.Y., Maruff, P., Pietrzak, R. H., Ellis, K. A., Darby, D., Ames, D., et al. (2014).Ab amyloid and cognitive change: Examining the preclinical and prodromal stages of Alzheimer's disease. Alzheimer's & Dementia, S1552-S5260 (13), 02939-02937.
20. Maruff, P., Lim, Y. Y., Darby, D., Ellis, K. A., Pietrzak, R. H., Snyder, P. J., et al. (2013). Clinical utility of the cogstate brief battery in identifying cognitive impairment in mild cognitive impairment and Alzheimer's disease. BMC Pharmacology & Toxicology, 1 (30), 1-11.
21. Masters, C. L., & Selkoe, D. J. (2012). Biochemistry of amyloid b-protein and amyloid deposits in Alzheimer Disease. In D. J. Selkoe, E. Mandelkow, & D. M. Holtzman (Eds.), The biology of Alzheimer disease (pp. 181-204). New York: Cold Spring Harbor Laboratory Press.
22. Mormino, E. C., Kluth, J. T., Madison, C. M., Rabinovici, G. D., Baker, S. L., Miller, B. L., et al. (2008). Episodic memory loss is related to hippocampal-mediated b-amyloid deposition in elderly subjects. Brain, 132, 1310-1323.
23. Oh, H., Madison, C. M., Villeneuve, S., Markley, C., & Jagust, W. J. (2014). Association of gray matter atrophy with age, b-amyloid, and cognition in aging. Cerebral Cortex, 24 (6), 1609-1618.
24. Ong, K. T., Villemagne, V. L., Bahar-Fuchs, A., Lamb, F., Langdon, N., Catafau, A. M., et al. (2014).Ab imaging with 18F-florbetaben in prodromal Alzheimer's disease: A prospective outcome study. Journal of Neurology, Neurosurgery, & Psychiatry, Jun 26, pii: jnnp-2014-308094.
25. Ourselin, S., Roche, A., Subsol, G., Pennec, X., & Ayache, N. (2001).Reconstructing a 3Dstructure fromserial histological sections. Image and VisionComputing, 19 (1-2), 25-31.
26. Preacher, K. J., Wichman, A. L., MacCallum, R. C., & Briggs, N. E. (2008). Latent growth curve modeling. CA, USA: SAGE Publications.
27. Roberts, R. O., Geda, Y. E., Knopman, D. S., Cha, R. H., Pankratz, V. S., Boeve, B. F., et al. (2008). The Mayo Clinic Study of Aging: Design and sampling, participation, baseline measures and sample characteristics. Neuroepidemiology, 30 (1), 58-69.
28. Rowe, C. C., Bourgeat, P., Ellis, K. A., Brown, B., Lim, Y. Y., Mulligan, R., et al. (2014). Predicting Alzheimer disease with b-amyloid imaging: Results from the Australian imaging, biomarkers, and lifestyle study of ageing. Annals of Neurology, 74 (6), 905-913.
29. Rowe, C. C., Ellis, K. A., Rimajova, M., Bourgeat, P., Pike, K. E., Jones, G., et al. (2010). Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiology of Aging, 31, 1275-1283.
30. Villemagne, V. L., Burnham, S., Bourgeat, P., Brown, B., Ellis, K. A., Salvado, O., et al. (2013). Amyloidb deposition, neurodegeneration and cognitive decline in sporadic Alzheimer's disease: A prospective cohort study. Lancet Neurology, 12, 357-367.
31. Wirth, M., Villeneuve, S., Haase, C. M., Madison, C. M., Oh, H., Landau, S. M., et al. (2013). Associations between Alzheimer disease biomarkers, neurodegeneration, and cognition in cognitively normal older people. JAMA Neurology, 70 (12), 1512-1519.